Presidential Symposium
Cutting edge molecular target therapy for hematologic malignancies

[PSY-4] Cutting edge of molecular target therapy for Multiple Myeloma

Katja C Weisel (Hematology, Oncology and Immunology, University of Tuebingen, Germany)

Katja Christina Weisel, MD, is an Associate Professor in Haematology/Oncology in the department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology at the University of Tbingen, Germany. Prof. Weisel received her medical degree from the Medical School of the University of Ulm, Germany, and did her clinical residency in internal medicine at the University of Tbingen. She did a postdoctoral research fellowship in the laboratory of Developmental Hematopoiesis at the Memorial Sloan-Kettering Cancer Center in New York, NY, USA, She completed her medical fellowship in internal medicine and Hematology, Oncology at the University of Tbingen. Here, she is heading the outpatient care unit of the department. Prof. Weisel is since 2006 leading the Tbingen myeloma program. Her myeloma research interests focus on treatment optimization for high-risk myeloma, renally impaired myeloma patients, refractory myeloma patients and radiographic methods monitoring myeloma disease. She is member of the steering committee of the german speaking multiple myeloma group (GMMG). Prof. Weisel is coinvestigator in all GMMG trials and is the lead investigator of 3 GMMG trials, including the GMMG-CONCEPT trial investigating a novel first-line treatment in high-risk myeloma patients. Furthermore, she was the principle investigator in several national and international phase I-III trials. Prof. Weisel is member of the steering committee of the German Society for Hematology and Oncology (DGHO) and member of the International Myeloma Working Group (IMWG). She participated in more than 80 publications on multiple myeloma treatment and biology.